Researchers review Real-World use of neratinib in early breast cancer
NCT ID NCT05599334
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received the drug neratinib as extra treatment after their main therapy, through a special early access program in Europe. The goal was to describe the patients' ages, genders, health conditions, and cancer details. No new treatment was given; the study simply collected existing information to learn more about who received neratinib and how it was used.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria di Parma
Parma, Italy
-
CHU Brest - Hôpital Morvan
Brest, France
-
Centre Bourgogne
Lille, France
-
Clinique Saint-Luc Bouge
Bouge, Belgium
-
Complejo Hospitalario de Jaén
Jaén, Spain
-
Hopital Prive La Louviere
Lille, France
-
Hospital Clinic Barcelona
Barcelona, Spain
-
Hospital General Universitario Gregorio Marañon
Madrid, Spain
-
Hospital General Universitario de Valencia
Valencia, Spain
-
Hospital General de Catalunya
Sant Cugat del Vallès, Spain
-
Hospital LLuís Alcanyís de Xàtiva
Valencia, Spain
-
Hospital Quironsalud Barcelona
Barcelona, Spain
-
Hospital Ruber Internacional
Madrid, Spain
-
Hospital Teknon Barcelona
Barcelona, Spain
-
Hospital Universitari Arnau de Vilanova
Lleida, Spain
-
Hospital Universitario Clinico San Carlos
Madrid, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Spain
-
IRCCS Ospedale Policlinico San Martino
Genova, Italy
-
Instituto Valenciano de Oncología IVO, Servicio de Oncología Médica C/ Beltran Baguena
Valencia, 46009, Spain
-
Istituto Nazionale Tumori Fondazione G. Pascale, Dipartimento di Senologia Via Mariano Semmola
Naples, 80131, Italy
-
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, Belgium
-
Multidisciplinary Breast Unit of the University Hospital Leuven and Sint-Andries Hospital
Leuven, 3000, Belgium
-
Ospedale San Donato- ASL 8 Arezzo
Arezzo, Italy
-
Ospedale Santa Croce
Fano, Italy
-
University Hospital Center Zagreb, Department of Oncology, Breast Unit
Zagreb, 10000, Croatia
Conditions
Explore the condition pages connected to this study.